Adial Pharmaceuticals ADIL 深 滬
等待開盤 09-10 09:30:00 美东时间
0.3525
+0.003
+0.86%
華盛通- 最 高0.36
- 今 開0.34
- 成交量 29.63万股
- 最 低 0.34
- 昨 收 0.3495
- 總市值 761.91万
- 52周最高 1.30
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 0.22
- 委 比 -67.16%
- 總股本 2161.46万
- 歷史最高 236.00
- 量 比 1.03
- 振 幅 5.72%
- 歷史最低 0.22
- 每 手 1
- 風險率 0.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adial Pharma Receives 180-Day Nasdaq Extension To Regain Minimum Bid Price Compliance
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today
09-03 20:42
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
Adial Pharmaceuticals has been granted an additional 180 days until March 2, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 for 10 consecutive business days during this period. Adial, focused on addiction treatments, recently tested its lead drug AD04 in a Phase 3 trial for Alcohol Use Disorder, showing promising results. The company will monitor its st...
09-03 12:30
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
<p>U.S. Senate support for expanding clinical trial endpoints beyond abstinence in substance use disorders validates Adial's patient-centric approach to AUD treatment. The new legislative measures, which passed with bipartisan support, encourage the FDA to adopt alternative endpoints such as reduced craving and alcohol use, aligning with Adial's strategy for AD04, a serotonin-3 receptor antagonist targeting AUD. CEO Cary Claiborne highlighted the...
08-20 12:30
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals updated on its progress, including a successful FDA Phase 2 meeting for its lead drug AD04 targeting Alcohol Use Disorder (AUD). Key Phase 3 trial elements were agreed upon, and collaborations with Cytel for genetic subgroup identification and manufacturers for supply chain assurance were highlighted. The company emphasized a disciplined approach to achieve Phase 3 success. Financials showed a $5.9M cash balance and reduced ...
08-14 12:30
Adial Pharmaceuticals Q2 EPS $(0.18) Beats $(0.25) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.25) by 28 percent. This is a 69.49 percent increase over losses of $(0.59) per share
08-14 05:43
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
Adial Pharmaceuticals successfully completed its End of Phase 2 meeting with the FDA, paving the way for advancing AD04 into Phase 3 clinical trials for treating Alcohol Use Disorder (AUD) in heavy drinkers with specific genotypes, including the AG+ genotype. FDA feedback provided validation for the adaptive trial design, strengthening Adial's position in discussions with potential partners. AD04 is a serotonin-3 receptor antagonist with potentia...
08-06 12:00
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Shares of CommScope Holding Company, Inc. (NASDAQ:COMM) rose sharply in pre-mar...
08-04 18:55
Adial Pharmaceuticals Enters New Sales Agreement
An announcement from Adial Pharmaceuticals ( ($ADIL) ) is now available. On Aug...
08-02 05:18
Adial Pharmaceuticals Approves Share Increase at Annual Meeting
Adial Pharmaceuticals ( ($ADIL) ) has provided an announcement. On August 1, 20...
08-02 04:59
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing Requirement
Adial Pharmaceuticals announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1), maintaining stockholders' equity of at least $2.5 million. CEO Cary Claiborne highlighted this as a key step in reinforcing investor confidence and supporting long-term growth, reflecting disciplined financial management. The公司 focuses on developing treatments for addiction, with its lead product AD04 showing promise in reducing heavy drinking in AUD p...
07-16 12:30
